Paid Clinical Trials Milwaukee

Discover 750 paid clinical trials in Milwaukee, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 750

ASP2138 with Cancer TreatmentsA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Recruiting

PHASE1

Sponsor:

Astellas Pharma Global Development, Inc.

Location:

Milwaukee WI, Chicago IL, Westwood KS, Winston-Salem NCshow 7 more

Code:

NCT05365581

Conditions

Gastric Adenocarcinoma

Gastroesophageal Junction (GEJ) Adenocarcinoma

Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASP2138

Pembrolizumab

Oxaliplatin

Leucovorin

Fluorouracil

Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Milwaukee WI, Green Bay WI, Merrillville IN, Owosso MIshow 59 more

Code:

NCT05156281

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

BIIB091 & DRFA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting

PHASE2

Sponsor:

Biogen

Location:

Milwaukee WI, Madison WI, Fort Wayne IN, Cincinnati OHshow 19 more

Code:

NCT05798520

Conditions

Relapsing Forms of Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

BIIB091

DRF

Placebo

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Milwaukee WI, Wauwatosa WI, West Allis WI, Cudahy WIshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Milwaukee WI, Wauwatosa WI, West Allis WI, Cudahy WIshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Milwaukee WI, Madison WI, Chicago IL, Grand Rapids MIshow 104 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

SeralutinibEfficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Milwaukee WI, Chicago IL, Iowa City IA, Ann Arbor MIshow 51 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Milwaukee WI, Park Ridge IL, Madison WI, Elmhurst ILshow 143 more

Code:

NCT05952557

Conditions

Breast Cancer, Early Breast Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Camizestrant

Tamoxifen

Anastrozole

Letrozole

Exemestane

FelzartamabA Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

Recruiting

PHASE3

Sponsor:

Biogen

Location:

Milwaukee WI, Columbus OH, Omaha NE, Nashville TNshow 7 more

Code:

NCT06685757

Conditions

Antibody-mediated Rejection

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Felzartamab

Placebo

MilvexianA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Gurnee IL, Chicago IL, Downers Grove IL, Palos Hills ILshow 163 more

Code:

NCT05754957

Conditions

Acute Coronary Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Milvexian

Placebo